PMID- 28756651
OWN - NLM
STAT- MEDLINE
DCOM- 20181004
LR  - 20181202
IS  - 1752-699X (Electronic)
IS  - 1752-6981 (Linking)
VI  - 12
IP  - 4
DP  - 2018 Apr
TI  - Relationship between driver gene mutations, their relative protein expressions 
      and survival in non-small cell lung carcinoma in Macao.
PG  - 1416-1423
LID - 10.1111/crj.12670 [doi]
AB  - OBJECTIVES: We report the status of most common gene mutations in non-small cell 
      lung carcinoma (NSCLC) in Macao, and explore the relationship between each gene 
      mutation and clinicopathologic features and survival. METHODS: EGFR, KRAS and 
      BRAF mutations were detected by PCR in 122 cases of NSCLC. ALK translocation and 
      MET amplification were detected by fluorescence in situ hybridization (FISH). MET 
      and thyroid transcription factor (TTF-1) were investigated by 
      immunohistochemistry. Clinical data were collected for analyzing their 
      correlation with the gene mutations. RESULTS: The mutation of EGFR, KRAS and BRAF 
      was detected in 48 (39.3%), 13 (10.7%) and 3 (2.5%) of 122 cases of NSCLC, 
      respectively. ALK translocation and MET amplification were detected in 7 (5.7%) 
      and 3 cases (2.5%). The rate of EGFR mutation was significantly higher in female 
      and non-smoker patients. In TTF-1 positive cases EGFR mutation was more frequent. 
      Age of the patients over 62-year old was correlated with KRAS mutations. The 
      concordance between ALK IHC and FISH was 58.3%. The MET protein in the cases with 
      MET amplification was 100% positive. The survival was lower in the patients with 
      positive MET protein than those with negative. MET protein was an independent 
      prognostic factor for NSCLC. CONCLUSIONS: EGFR mutation occurred frequently in 
      the female never smoke patients with NSCLC. KRAS mutation was more common in old 
      patients. Negative MET protein expression could be used as a negative predictive 
      marker of MET amplification. MET protein expression was an independent prognostic 
      factor for NSCLC.
CI  - (c) 2017 John Wiley & Sons Ltd.
FAU - Chan, Kin Iong
AU  - Chan KI
AD  - Department of Pathology, Kiang Wu Hospital, Macau Special Administrative Region, 
      Macau, China.
FAU - Vong, Hong Ting
AU  - Vong HT
AD  - Department of Pathology, Kiang Wu Hospital, Macau Special Administrative Region, 
      Macau, China.
FAU - Sin, Lai Fong
AU  - Sin LF
AD  - Department of Pathology, Kiang Wu Hospital, Macau Special Administrative Region, 
      Macau, China.
FAU - Yip, Yuk Ching
AU  - Yip YC
AD  - Department of Pathology, Kiang Wu Hospital, Macau Special Administrative Region, 
      Macau, China.
FAU - Zhong, Xue Yun
AU  - Zhong XY
AD  - Department of Pathology, Medical School, Jinan University, Guangzhou 510632, 
      China.
FAU - Wen, Jian Ming
AU  - Wen JM
AUID- ORCID: 0000-0002-9859-5203
AD  - Department of Pathology, Kiang Wu Hospital, Macau Special Administrative Region, 
      Macau, China.
LA  - eng
PT  - Journal Article
DEP - 20170809
PL  - England
TA  - Clin Respir J
JT  - The clinical respiratory journal
JID - 101315570
RN  - 0 (DNA, Neoplasm)
RN  - 0 (KRAS protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - EC 2.7.11.1 (BRAF protein, human)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins B-raf)
RN  - EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras))
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biopsy
MH  - Carcinoma, Non-Small-Cell Lung/epidemiology/*genetics/pathology
MH  - DNA Mutational Analysis
MH  - DNA, Neoplasm/*genetics
MH  - ErbB Receptors/*genetics
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Incidence
MH  - Lung Neoplasms/epidemiology/*genetics/pathology
MH  - Macau/epidemiology
MH  - Male
MH  - Middle Aged
MH  - *Mutation
MH  - Neoplasm Staging
MH  - Polymerase Chain Reaction
MH  - Proto-Oncogene Proteins B-raf/*genetics
MH  - Proto-Oncogene Proteins p21(ras)/*genetics
MH  - Survival Rate/trends
OTO - NOTNLM
OT  - BRAF
OT  - Kirsten rat sarcoma
OT  - MET
OT  - anaplastic lymphoma kinase
OT  - epidermal growth factor receptor
OT  - non-small cell lung carcinoma
EDAT- 2017/08/02 06:00
MHDA- 2018/10/05 06:00
CRDT- 2017/07/31 06:00
PHST- 2017/03/17 00:00 [received]
PHST- 2017/06/23 00:00 [revised]
PHST- 2017/07/25 00:00 [accepted]
PHST- 2017/08/02 06:00 [pubmed]
PHST- 2018/10/05 06:00 [medline]
PHST- 2017/07/31 06:00 [entrez]
AID - 10.1111/crj.12670 [doi]
PST - ppublish
SO  - Clin Respir J. 2018 Apr;12(4):1416-1423. doi: 10.1111/crj.12670. Epub 2017 Aug 9.